A primary study: high-throughput sequencing analysis of amniotic fluid microbiota in 50 high-risk pregnant women during the second trimester
Frontiers in Cellular and Infection Microbiology · 22.04.2026 · 16
DOI: 10.3389/fcimb.2026.1748232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 22.04.2026. Verfasst von Junhua Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The affiliated Women and Children's Hospital of Ningbo University, Ningbo, Zhejiang, China. Hauptthemen laut MEDLINE: Amniotic Fluid, Pregnancy Trimester, Second, Microbiota, Bacteria. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Whether bacteria exist in the pregnancy uterus without pathological infection has long been a controversial topic. Through this study, we aim to determine whether characteristic amniotic fluid microbiota exists in the uterus of high-risk pregnant women during the second trimester.
Methods
This study recruited high-risk pregnant women in the second trimester from September 1, 2024, to August 30, 2025, and recorded their age and gestational age. Amniotic fluid samples were obtained through amniocentesis under strictly sterile conditions, and 16S rRNA high-throughput sequencing was performed on the samples. The inclusion criteria mainly consisted of: advanced maternal age, non-invasive prenatal test results indicating chromosomal abnormalities, abnormal fetal ultrasound findings, history of adverse pregnancy outcomes, and high-risk Down syndrome screening results.
Results
This study included a total of 50 high-risk pregnant women who underwent amniocentesis. The results showed that bacteria were present in all amniotic fluid samples, primarily composed of Actinobacteriota and Proteobacteria . There was no difference in amniotic fluid microbiota diversity between pregnant women under 35 years old and those 35 years or older; however, the abundances of Cutibacterium and Leifsonia differed between the two groups. A slight difference in microbiota diversity was observed between women with gestational ages below 20 weeks and those at 20 weeks or above, but no significant difference was found in microbial composition between the two groups.
Conclusion
There was bacterial DNA in amniotic fluid of high-risk pregnant women in the second trimester, with Actinobacteriota and Proteobacteria being the predominant phyla, showing limited correlation with maternal age or gestational age. This study provided evidence for the presence of microorganisms in amniotic fluid during pregnancy and might offer some preliminary data for future research related to eugenics and reproductive health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, The affiliated Women and Children's Hospital of Ningbo University, Ningbo, Zhejiang, China.
- Department of Pediatrics, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei, China.
Zitieren
APA
Wu, J., Lu, Y., Zheng, Z., Zheng, J., & Fu, Q. (2026). A primary study: high-throughput sequencing analysis of amniotic fluid microbiota in 50 high-risk pregnant women during the second trimester. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1748232
Vancouver
Wu J, Lu Y, Zheng Z, Zheng J, Fu Q. A primary study: high-throughput sequencing analysis of amniotic fluid microbiota in 50 high-risk pregnant women during the second trimester. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1748232
BibTeX
@article{Wu2026,
author = {Wu, Junhua and Lu, Yanbo and Zheng, Zhouyong and Zheng, Jishan and Fu, Qiang},
title = {A primary study: high-throughput sequencing analysis of amniotic fluid microbiota in 50 high-risk pregnant women during the second trimester},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1748232}
}
EUVIMED